本文へ移動
cccskills
無料GitHub で公開

es-contraindicate-prepubertal-pubertal-blocking-hormones

This skill recommends against initiating puberty blocking or gender-affirming hormone treatment in prepubertal children diagnosed with gender dysphoria or gender incongruence. Clinical triggers include a young child presenting with GD/gender incongruence and caregivers or clinicians considering hormone intervention.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.6 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Contraindicate puberty blocking and gender-affirming hormones in prepubertal children

STEP 1 — Gather Information

Collect patient age, Tanner stage (prepubertal defined as G1/B1), confirmed diagnosis of GD/gender incongruence per DSM-5/ICD-10 criteria, psychosocial history, and ensure no pubertal changes are present; if any data are missing, defer decision until information is obtained.

STEP 2 — Rule In / Rule Out

Is the child prepubertal (Tanner G1/B1) with a confirmed diagnosis of GD/gender incongruence? If yes, proceed to contraindication pathway; if no, evaluate for puberty-appropriate hormone therapy or alternative management.

STEP 3 — Classify or Stratify

Classify hormone therapy as contraindicated in this prepubertal child with GD/gender incongruence based on strong recommendation against treatment.

STEP 4 — Decide

Withhold puberty blocking and gender-affirming hormones; initiate psychosocial support, monitor for pubertal onset every 3–6 months, and reassess hormone therapy eligibility after puberty begins.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on bone age or parental report to determine pubertal status; do not treat based on social transition alone; do not ignore comorbid psychiatric conditions that require separate management; do not use hormones to treat non‑GD conditions such as anxiety or depression; do not initiate blockers or sex steroids in prepubertal children even if they have socially transitioned.

Concrete Clinical Example

A 7‑year‑old assigned male at birth presents with persistent insistence of being female, preference for female toys and clothing, and distress when referred to as male. Parents inquire about starting puberty blockers to prevent future masculinization. Evaluation confirms Tanner stage G1/B1, DSM‑5 criteria for GD are met, and no pubertal changes are observed. Following the guideline, clinicians decline hormone treatment, provide gender‑affirming psychosocial support, and schedule reevaluation at the first signs of puberty.

Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する